Optimi Health has Health Canada authorization for a Phase 2 trial of natural psilocybin in up to 200 adults with major depressive disorder. Dosing starts in 2027, and a new House bill could decide whether mushroom-derived drugs are worth taking through the FDA.
The post Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity appeared first on Psychedelics Today.
